BioLineRx (BLRX) and Hemispherian Showcase New GLIX1 Data Ahead of ASCO 2026 as First-in-Human GBM Trial Enrolls

On May 22, 2026 BioLineRx and Hemispherian spotlighted GLIX1 at ASCO 2026, backed by strong preclinical data and an enrolling Phase 1/2a glioblastoma trial.

New results show GLIX1’s TET2-targeting mechanism and synergistic activity with PARP inhibitors, reinforcing its potential in glioblastoma and broader solid tumor indications.